Navigation Links
Yongye Biotechnology International Raises $9.4 Million in Private Placement
Date:9/10/2008

BEIJING, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals in the People's Republic of China, today announced that it closed a private placement financing with certain institutional investors led by Black River Asset Management, pursuant to which the Company issued 6,073,006 shares of its common stock for gross proceeds of approximately $9.4 million. Roth Capital Partners served as the placement agent.

The Company intends to use the proceeds from this placement to begin restructuring Yongye Nongfeng Biotechnology Co. ("Yongye Nongfeng"), the Cooperative Joint Venture (CJV) through which Yongye conducts operations in China, and for working capital. The initial steps in the restructuring will be to purchase production equipment located at an existing 2,000 Tonnes Per Annum (TPA) production line that is owned by the Company's current contract manufacturer, Inner Mongolia Yongye Biotechnology Company, Ltd. ("Inner Mongolia Yongye"), which is scheduled to occur by the end of October 2008, and to construct a new 8,000 TPA production facility, which is scheduled to be completed by the middle of October 2008. The combined 10,000 TPA capacity of both facilities will allow the Company to produce its own finished goods in the quantities needed to fulfill its current and future sales goals. After the completion of the equipment purchase and the integration of the equipment with the Company's new 8,000 TPA facility, the Company will discontinue its current exclusive contract manufacturing agreement with Inner Mongolia Yongye. The final step to the restructuring will be to transfer to the CJV all of the land, buildings and permits that belong to Inner Mongolia Yongye, and the new manufacturing facility, which will make the CJV the Company's own manufacturing and distribution entity. The full restruc
'/>"/>

SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Yongye Biotechnology International Announces Second Quarter Results
2. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
5. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
6. InNexus Biotechnology Strengthens Patent Team With New Leadership
7. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
10. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... OncoTAb, Inc., a University ... announced that Pinku Mukherjee, Ph.D. has received the ... Governors’ highest faculty honor. Mukherjee received the award, which ... her innovative research and development of cancer diagnostics and ... crowning moment in my scientific career,” said Mukherjee, OncoTAb ...
(Date:5/1/2015)... DIEGO , May 1, 2015 ... company engaged in the development of biosimilar therapeutics ... announced today that its first quarter 2015 financial ... 2015, before the open of market. At 8:30 am ... call to discuss the financial results and provide ...
(Date:5/1/2015)... -- A new report by  visiongain  forecasts ... $22.4bn in 2019. That revenue forecast and others appear ... 2015-2025 ,  published in March 2015. ... forecasts and qualitative analyses of the antithrombotic drugs market. ... London, UK . It produces analyses ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme ... patients refractory to conventional therapy.  Chronic gout that is ... failed to normalize serum uric acid and whose signs ...
... Calif., Sept. 14 The launch of IntriMed ... Innovation Center in Oxnard, Calif. were announced today ... design and manufacture of ultra-precise components for the ... 23 year heritage of engineering innovation, IntriMed ( ...
... (Nasdaq: BSTC ), a biopharmaceutical company developing ... President, Tom Wegman, will present at the upcoming UBS ... at 7:30am ET at the Grand Hyatt New York ... of the presentation can be accessed under "Calendar of ...
Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 2IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 3
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... why premature birth is a growing problem in the United ... that pre-pregnancy depressive mood appears to be a risk factor ... however, have nearly two times the odds of having a ... a University of Washington assistant professor of social work and ...
... pregnant women hinders brain development in their children ... thyroid hormone levels in the fetal brain, a ... Wednesday at The Endocrine Society,s 91st Annual Meeting ... moderate drinking during pregnancycan cause neurodevelopmental disorders, such ...
... , This release is available in ... this is particularly true for cancer medicine. The ... further increased if research results are swiftly transferred from ... research transfer, also called translational research, will now be ...
Cached Biology News:Pre-pregnancy depressed mood may heighten risk for premature birth 2Pre-pregnancy depressed mood may heighten risk for premature birth 3Specific genetic cause of fetal alcohol-related developmental disorders found 2German Research Minister Schavan: 'Rapid knowledge transfer can safe lives' 2German Research Minister Schavan: 'Rapid knowledge transfer can safe lives' 3
Human ABCG2 MAb (Clone 5D3)...
... The Beacon 2000 One-Step FP ... characteristic high and low fluorescence polarization ... users of the Beacon 2000 System. ... the polarization values generated by their ...
...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
Biology Products: